Seattle Archives

PCa Commentary | Volume 174 – February 2023

Posted by Edward Weber, MD | Feb 2023

This Commentary discusses the importance of considering both PSA and PSA doubling time for determining biochemical recurrence.

Posted by Edward Weber, MD | Jan 2023

This Commentary discusses Bipolar Androgen Therapy: an effective, but likely underused, option in the sequence of treatments for mCRPC.

Posted by Edward Weber, MD | Dec 2022

This Commentary discusses selecting men for MDT+ADT versus MDT alone in the oligometastatic prostate cancer space.

Posted by Edward Weber, MD | Nov 2022

This Commentary explores treatment regimens combining enzalutamide, apalutamide, or darolutamide with androgen deprivation for nmCRPC.

Posted by Edward Weber, MD | Sep 2022

This Commentary looks at ADT and radiotherapy, as well as evolution of cellular resistance to ADT therapy and potential treatment.